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Aims:  Hyperthyroidism  includes  several  clinical  and  histopathological  situations.  Surgery  is  commonly
indicated  after  failure  of  medical  treatment.  The  aim  of  this  study  was to analyze  the indications  and
complications  of  surgery  as  well  as  endocrine  results.
Materials  and methods:  Patients  operated  on for  hyperthyroidism  between  2004  and  2012  were  included
in  a retrospective  study.  Total  thyroidectomy  was  performed  for  Graves’  disease,  toxic  multinodular
goiter  and  amiodarone-associated  thyrotoxicosis;  patients  with  toxic  nodule  underwent  hemithyroidec-
tomy.  Pathologic  analysis  assessed  surgical  specimens;  postoperative  complications  and  resolution  of
hyperthyroidism  were  noted.
Results:  Two  hundred  patients  from  15  to 83  years  old  were  included.  One  hundred  and  eighty-eight
underwent  primary  surgery  and  12  were  re-operated  for recurrent  goiter  (6 with  subtotal  thyroidectomy
for  multinodular  goiter 25  years  previously;  6 with  hemithyroidectomy  for  solitary  nodule  15 years
previously).  Eighty-two  patients  suffered  from  toxic  multinodular  goiter,  78  from  Graves’  disease,  35 from
solitary toxic  nodules  and  5 from  amiodarone-associated  thyrotoxicosis.  Fourteen  papillary  carcinomas
(including  11  papillary  microcarcinomas)  and 34  healthy  parathyroid  glands  (17%)  were  identiﬁed  in
the  pathological  specimens.  Postoperative  complications  comprised  4% permanent  recurrent  laryngeal
nerve  palsy (1 year  follow-up),  9%  hematoma  requiring  surgical  revision,  and  3% deﬁnitive  hypocalcemia.
Normalization  of thyroid  hormone  levels  was  observed  in 198  patients.  Two  recurrences  occurred  due  to
incomplete  resection  (1 case  of  Graves’  disease  and  1 intrathoracic  toxic  goiter  that occurred  respectively
18  and  5 months  after  resection).  Postoperative  complications  were  more  frequent  in multinodular  goiter
(23%) than  in Graves’  disease  (13%)  (ns: P  >  0.05).
Conclusion:  Surgical  management  of  hyperthyroidism  enables  good  endocrinal  control  if surgery  is com-
plete.  Patients  need  to be fully  informed  of  all possible  postoperative  complications  that  could  occur,
especially  vocal  ones.  Long-term  follow-up  is necessary  to  detect  recurrence,  which  can  occur  more
than  20  years  after  partial  thyroidectomy  surgery.  Surgery  allows  early  diagnosis  of  12.5%  of  papillary
carcinomas.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Hyperthyroidism is deﬁned as excessive secretion of iodinated
hyroid hormones: triiodothyronine (T3) and thyroxine (T4). The
ssociated target tissue disorders are known as thyrotoxicosis.
sthenia, weight-loss, anxiety, palpitations and thermophobia are
Abbreviations: SATDs, synthetic anti-thyroid drugs; MNG, multinodular goi-
er;  RLNP, recurrent laryngeal nerve palsy; STT, subtotal thyroidectomy; TT, total
hyroidectomy.
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879-7296/© 2014 Elsevier Masson SAS. All rights reserved.the main symptoms [1]; associated with goiter or exophthalmia,
they are suggestive of this metabolic disorder.
Hyperthyroidism affects 1–3% of the general population: 2% of
female and 0.2% of male subjects [1]. Anatomo-clinical situations
vary: the most frequent is Graves’ disease, accounting for 50–80%
of cases [2].
Other causes comprise toxic multinodular goiter (MNG), toxic
adenoma and amiodarone-associated hyperthyroidism.
Several treatment options are available, depending on the
pathology involved: synthetic anti-thyroid drugs (SATDs), radioac-
tive iodine, percutaneous ethanol injection, or surgery.
Treatment choice has long been controversial. The risk of
postoperative complications such as hypocalcemia [3], hematoma
or recurrent laryngeal nerve palsy (RLNP) [4] following total
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Table  1
Preoperative demographic data.
n (%) Gender
F/M
Age (years) Primary surgery Secondary surgery
n Age n Age
MNG  82 (41%) 33/8 55.7 65 (79%) 55 17 (21%) 61
Graves’ disease 78 (39%) 34/5 38.7 40 (51%) 41 38 (49%) 36.5
Solitary nodule 35 (17.5%) 26/9 48.8 29 (83%) 48 6 (17%) 53.8
Amiodarone 5 (2.5%) 1/4 63.2 5 (100%) 63.2 0
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NG: multinodular goiter; n: number of cases.
hyroidectomy (TT) is classically elevated in case of hyperthy-
oidism, but surgery provides faster and more stable remission of
ndocrine disorder than conservative strategies [1], and also ear-
ier detection of thyroid cancer associated with endocrinopathy [5].
urgery is therefore a treatment of choice, notably following fail-
re of primary medical treatment (usually SATDs and/or radioactive
odine) [1].
The present study sought to analyze indications for and compli-
ations associated with surgery, and endocrine results according to
athology.
. Materials and methods
A retrospective study included patients operated on for hyper-
hyroidism by a single surgeon between 2004 and 2012. TT
as performed for Graves’ disease, toxic goiter and amiodarone-
ssociated hyperthyroidism, and lobo-isthmectomy for toxic
odule.
Two hundred patients (38 male [19%], 162 female [81%]), mean
ge 48 years (range, 15–83 years), were included over the 8-year
eriod. In 139 cases (69.5%), surgery was primary, and in 61 (30.5%)
econdary to either medical treatment or prior surgery.
Table 1 presents the main demographic data.
SATDs were prescribed in ﬁrst intention except for patients
oorly tolerating this medication or requiring urgent surgery, in
hich case beta-blockers were used.
Surgery was in all cases performed under general anesthesia
ith intubation. Inferior laryngeal nerve monitoring was not sys-
ematically used. Redon drains were systematically ﬁtted until
ostoperative D2.
Hospital stay was systematically for 48 hours. Preoperative and
ostoperative nasoﬁbroscopy (D2 and 1 month) were performed
n all cases. In patients with postoperative laryngeal immobility, a
inimum one-year of follow-up was achieved.
Calcemia was systematically assessed by D1, D2, D7 and D14,
nd at 2 months if not normal by D14.
All thyroidectomy specimens underwent pathologic analysis
earching for resected parathyroid gland and thyroid carcinoma.
Transient and deﬁnitive hypocalcemia, RLNP (deﬁnitive if per-
istent at 12 months), hematoma requiring surgical revision and
ecurrent endocrinopathy were recorded.
Statistical analysis used Chi2 or Fisher exact test; the signiﬁcant
hreshold was set at 0.05.
. Results
Surgical strategy was determined by various factors: desire
or pregnancy, carbimazole-induced agranulocytosis, compressive
igns, suspect cytology, and ophthalmopathy.Twelve of the 61 patients for whom surgery was  deferred (6%)
ad had previous procedures: 6 subtotal thyroidectomies (STT) for
oiter 25 years before index surgery, and 5 lobo-isthmectomies for
olitary nodule 15 years or, in 1 case, 30 years before index surgery.139 (69.5%) 51.8 61 (30.5%) 50.4
Forty-nine (24.5%) were operated on following medical failure (23
with recurrence at a mean 5 years; 18 failures of ongoing medical
treatment including 5 cases of carbimazole-induced agranulocyto-
sis). Eight patients had previously received ≥ 1 dose of iodine 131.
Fig. 1 presents the factors for treatment strategy.
Pathologic specimen analysis detected 25 malignant lesions
(12.5%): 3 papillary thyroid carcinomas (1.5%) and 22 papillary
microcarcinomas (11%). A healthy parathyroid gland was resected
in 17% of cases (34 patients). Table 2 shows pathology results.
Table 3 presents the main complications.
There were no deaths during follow-up.
Of the 18 patients (9%) with postoperative hematoma, 17% were
on anticoagulation treatment compared to 13% of patients without
(ns: P = 0.6).
RLNP was noted in 4 patients preoperatively and a fur-
ther 13 postoperatively, 5 of whom recovered normal laryngeal
motion within the year. Two  patients had laryngeal diplegia:
unilateral laser cordectomy was  performed on the day of pri-
mary surgery in 1 case and 1 month later in the other; no
tracheotomy was required. Six months after surgery, clinical eval-
uation noted intelligible voice, with 1 mobile vocal fold and the
other immobile in a paramedian position. In the other patient
bilateral palsy and dysphonia was noted at 1 year. There was
no RLNP in patients undergoing revision surgery for compressive
hematoma.
Twenty percent of patients had hypocalcemia by D2, deﬁnitive
in only 3%; 9% of patients with resected parathyroid gland devel-
oped deﬁnitive hypocalcemia; preserved parathyroid gland was
associated with 2% deﬁnitive hypocalcemia; the difference, how-
ever, was  non-signiﬁcant (P > 0.05).
After surgery, 2 cases of recurrence were noted (1% of patients):
1 of Graves’ disease after STT, and 1 intrathoracic nodule left after
MNG  resection 5 months previously.
4. Discussion
4.1. Treatment indications
In thyrotoxicosis, hyperthyroidism requires rapid treatment to
avoid recurrence and allow amiodarone treatment if necessary.
Strategy depends on pathology, health status and acceptable risk
[1].
In Europe, SATDs are the ﬁrst-line attitude in Graves’ disease.
They are usually effective, but only within 4–6 weeks, and require
prolonged treatment, cross-placental and lacteal barriers and may
exceptionally (< 1%) induce agranulocytosis [1]. Above all, long-
term efﬁcacy is only moderate, with a 50% relapse rate at 1 year
[6].
Radioactive iodine may  be a ﬁrst-line attitude in Graves’ dis-
ease and small MNG  [1], and is the second-line treatment of choice
after failure of SATDs in Graves’ disease. However, it is limited by
numerous contraindications, and the rate of failure is estimated at
21% [7].
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Fig. 1. Factors guiding therapeutic decision-making. MNG: multinodular goiter; ttt: treatment; SATDs: synthetic anti-thyroid drugs.
Table 2
Pathology results on specimen.
Papillary carcinoma pc Malignant lesion Benign lesion Parathyroid+
MNG  (82) 3 (3.6%) 11 (13.4%) 14 (17%) 68 (83%) 12 (15%)
Graves’ disease (78) 0 8 (10.2%) 8 (10.2%) 70 (90%) 10 (13%)
Nodule (35) 0 3 (8.6%) 3 (8.6%) 32 (91.5%) 12 (34%)
Amiodarone (5) 0 0 0 5 (100%) 0 (0%)
Total  (200) 3 (1.5%) 22 (11%) 25 (12.5%) 175 (87.5%) 34 (17%)
MNG: multinodular goiter; pc: papillary microcarcinoma; parathyroid+: intra-specimen parathyroid gland.
Table 3
Postoperative complications.
RLNP at 2 months Deﬁnitive
RLNP
Transient hypoCa Deﬁnitive hypoCa Hematoma Total deﬁnitive complications
MNG  (82) 8 (10%) 6 (7.3%) 19 (23.1%) 4 (4.8%) 9 (11%) 10 (12%)
Graves’ disease (78) 3 (3.8%) 1 (1.3%) 16 (20.5%) 2 (2.5%) 7 (9%) 3 (4%)
Nodule (35) 1 (2.8%) 0 4 (11.4%) 0 2 (5.7%) 0
Amiodarone (5) 1 (20%) 1 (20%) 1 (20%) 0 0 (0%) 1 (20%)
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LNP: recurrent laryngeal nerve palsy; hypoCa: hypocalcemia; MNG: multinodular
In solitary nodule, percutaneous ethanol injection has been
escribed when surgery is not feasible; the rate of failure is around
4%.
The main factors guiding treatment are goiter size and compres-
ive signs on imaging (AP chest X-ray or CT), suspected or diagnosed
oncomitant thyroid carcinoma, desire for pregnancy, and ophthal-
opathy [1]. In et al. [8] claim TT to be the most effective option
n recurrent Graves’ disease, from both a medical and an economic
oint of view.
.2. Surgical techniques
In Europe until the 2000s, STT was preferred, to avoid per-
anent postoperative opotherapy [9]. TT is now indicated, both
n Graves’ disease and MNG, providing optimal endocrine con-
rol without signiﬁcantly elevated risk of hypocalcemia or RLNP
10].In recent years, inferior laryngeal nerve monitoring was  devel-
ped for intra-operative laryngeal nerve assessment [9]; some
tudies reported reduced transient RLNP, but most did not note
 signiﬁcant beneﬁt [12,13].6 (3%) 18 (9%) 14 (7%)
r.
4.3. Postoperative complications
Surgery, unlike medical management, allows screening and
early treatment of thyroid carcinoma. The rate of thyroid cancer in
hyperthyroidism is non-negligible: 12.5% thyroid carcinoma rate
in the present study, and up to 18.3% in thyroidectomy specimens
reported elsewhere [5].
There were 34 parathyroid glands resected within the 200 spec-
imens (17%), with 20% transient and 3% deﬁnitive hypocalcemia.
Parathyroid resection can induce transient hypocalcemia, but in the
current series did not correlate with postoperative hypocalcemia.
Nair et al. [14] found hypocalcemia following TT to be signiﬁcantly
associated with parathyroid resection (P = 0.006). Overall deﬁnitive
hypocalcemia rates range from 0.4% to 4.2% [3,10], independently
of whether TT or STT was performed [15].
The present study noted a 6.5% rate of transient RLNP, 4%
deﬁnitive RLNP and 1% laryngeal diplegia, in agreement with the lit-
erature. Relative risk for RLNP was 1.54 in Guo et al.’s meta-analysis
[15]; rates vary from 1% [16] to 13% [17]. These studies, however,
did not always allow for the fact that the patients were in a situa-
tion of hyperthyroidism or had had prior surgery. Hyperthyroidism
is associated with a 2.5-fold higher risk of RLNP than in thyroid
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urgery under euthyroidism [18]. Likewise, in revision surgery,
LNP risk may  reach 17%. Laryngeal diplegia rates vary, depend-
ng on the series, from 0.4% to 1.7% [19,20], requiring tracheotomy
n 0.3% of cases [19]. In the present study with hyperthyroidism
n all cases, 25% of patients who developed deﬁnitive RLNP had
ndergone prior surgery. No tracheotomies were required.
Nine percent of patients developed postoperative hematoma;
nticoagulation treatment did not signiﬁcantly increase this risk
P > 0.05). However, low molecular weight heparin relay was sys-
ematic and withdrawn 12 hours before surgery. Lang et al. [21]
eported a 0.7% postoperative hematoma rate, but Godballe et al.
oted a 4.2% incidence for this complication [22]. In these reports,
ale gender and extensive resection were considered to be risk
actors. Lang et al. [21] also noted that previous thyroid surgery
ncreased risk 4-fold. Hyperthyroidism may  increase the risk for
ostoperative hematoma: Chiang et al. [23] noted a 11.5% rate for
ematoma after thyroidectomy for Graves’ disease, and a 6.5% inci-
ence for this complication in euthyroidism patients.
In the present study, whatever the procedure (lobo-
sthmectomy, TT or totalization) used, postoperative complication
ates did not differ (deﬁnitive RLNP, P = 0.9; deﬁnitive hypocal-
emia, P = 0.36; hematoma, P = 0.5). Hyperthyroidism thus indeed
eemed to be the determining factor in Graves’ disease and toxic
NG.
.4. Endocrine results
Two patients had recurrence of primary pathology. In 1, oper-
ted on for MNG, an intrathoracic nodule had been left after the
nitial surgical procedure 5 months earlier. In the other, there was
ecurrence of Graves’ disease 18 months after STT. According to the
iterature, surgery using TT is the most effective treatment modal-
ty in the long-term: Genovese et al. [7] reported a 0.3% recurrence
ate of hyperthyroidism after TT, compared to a 10% incidence with
TT. Bilosi et al. [24] demonstrated that the recurrence rate could
e as high as 14% if more than 6 g of parenchyma was  left after
urgery. In these various reports as in the present study, follow-up
id not exceed 5 years; but in our series 6% of patients had under-
one previous surgery. In unilateral thyroidectomy, recurrence was
f rapid onset: 5 lobo-isthmectomy patients recurred at 15 years,
ompared to 25 years in the 6 cases of STT. TT is to be preferred,
o avoid recurrence of hyperthyroidism. Even infraclinical hyper-
hyroidism increases cardiovascular risk: hypertension, ischaemic
eart disease and atrial ﬁbrillation [25].
. Conclusions
Surgery is the treatment of choice for rapid deﬁnitive con-
rol of hyperthyroidism, especially in Graves’ disease, MNG  and
miodarone-associated hyperthyroidism. Surgery must, however,
e complete; otherwise, residual thyroid tissue will lead to even
ery late recurrence (later than 20 years). Complications may  be
eﬁnitive, and require full patient information. Only surgery allows
arly diagnosis of associated papillary carcinoma.
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